caa a22 4500 606158774 CHVBK 20210128100621.0 cr unu---uuuuu 210128e20150401xx s 000 0 eng 10.1007/s10557-015-6575-8 doi (NATIONALLICENCE)springer-10.1007/s10557-015-6575-8 Effect of High Dose Statin Pretreatment on Endothelial Progenitor Cells After Percutaneous Coronary Intervention (HIPOCRATES Study) [Elektronische Daten] [A. Eisen, D. Leshem-Lev, H. Yavin, K. Orvin, A. Mager, E. Rechavia, T. Bental, O. Dadush, A. Battler, R. Kornowski, E. Lev] Background: Pretreatment with high-dose statins given before percutaneous coronary intervention (PCI) has been shown to have beneficial effects, in particular by reducing peri-procedural myocardial infarction. The mechanism of these lipid-independent beneficial statin effects is unclear. Circulating endothelial progenitor cells (EPCs) have an important role in the process of vascular repair, by promoting re-endothelization following injury. We hypothesized that statins can limit the extent of endothelial injury induced by PCI and promote re-endothelization by a positive effect on EPCs. We, therefore, aimed to examine the effect of high-dose statins given prior to PCI on EPCs profile. Methods: Included were patients, either statin naïve or treated chronically with low-dose statins, with stable or unstable angina who underwent PCI. Patients were randomized to receive either high-dose atorvastatin (80mg the day before PCI and 40mg 2-4h before PCI) or low- dose statin. EPCs profile was examined before PCI and 24h after it. Circulating EPCs levels were assessed by flow cytometry as the proportion of peripheral mononuclear cells co-expressing VEGFR-2+ CD133+ and VEGFR-2+ CD34+. The capacity of the cells to form colony forming units (CFUs) was quantified after 7days of culture. Results: Twenty three patients (mean age 61.4 ± 7.4years, 87.0% men) were included in the study, of which 12 received high-dose atorvastatin prior to PCI. The mean number of EPC-CFUs before PCI was higher in patients treated with high-dose atorvastatin vs. low-dose statins (165.8 ± 58.8 vs. 111.7 ± 38.2CFUs/plate, respectively, p < 0.001). However, 24h after the PCI, the number of EPC-CFUs was similar (188.0 ± 85.3 vs. 192.9 ± 66.5CFUs/plate in patients treated with high-dose atorvastatin vs. low- dose statins, respectively, p = 0.15). There were no statistical significant differences in FACS analyses between the 2 groups. Conclusions: The current study showed higher EPC- CFUs levels in patients treated with high-dose atorvastatin before PCI and a lower increment in EPC-CFUs after PCI. These findings could account for the beneficial effects of statins given prior to PCI, yet further investigation is required. Springer Science+Business Media New York, 2015 Endothelial progenitor cells nationallicence Hydroxymethyl glutaryl coenzyme A reductase inhibitors (Statins) nationallicence Percutaneous coronary intervention nationallicence Eisen A. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut Leshem-Lev D. The Felsenstein Medical Research Institute, Rabin Medical Center, Petah Tikva, Israel aut Yavin H. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut Orvin K. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut Mager A. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut Rechavia E. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut Bental T. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut Dadush O. The Felsenstein Medical Research Institute, Rabin Medical Center, Petah Tikva, Israel aut Battler A. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut Kornowski R. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut Lev E. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/2(2015-04-01), 129-135 0920-3206 29:2<129 2015 29 10557 https://doi.org/10.1007/s10557-015-6575-8 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10557-015-6575-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Eisen A. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut NATIONALLICENCE 700 1- Leshem-Lev D. The Felsenstein Medical Research Institute, Rabin Medical Center, Petah Tikva, Israel aut NATIONALLICENCE 700 1- Yavin H. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut NATIONALLICENCE 700 1- Orvin K. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut NATIONALLICENCE 700 1- Mager A. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut NATIONALLICENCE 700 1- Rechavia E. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut NATIONALLICENCE 700 1- Bental T. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut NATIONALLICENCE 700 1- Dadush O. The Felsenstein Medical Research Institute, Rabin Medical Center, Petah Tikva, Israel aut NATIONALLICENCE 700 1- Battler A. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut NATIONALLICENCE 700 1- Kornowski R. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut NATIONALLICENCE 700 1- Lev E. Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/2(2015-04-01), 129-135 0920-3206 29:2<129 2015 29 10557